Trials / Recruiting
RecruitingNCT07114315
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
A Phase II Clinical Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-center phase II clinical study consisting of two parts: Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer. Part II: To evaluate the safety and efficacy of AK112, either as monotherapy or in combination with AK130, in advanced pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK112 | Following a predefined dose and date. |
| DRUG | AK130 | Following a predefined dose and date. |
Timeline
- Start date
- 2025-09-19
- Primary completion
- 2027-08-01
- Completion
- 2028-08-01
- First posted
- 2025-08-11
- Last updated
- 2026-03-03
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07114315. Inclusion in this directory is not an endorsement.